A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT06417008
Phase
PHASE2 / PHASE3
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HS-20117
  • Aumolertinib
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Males or females aged 18 - 75 years (inclusive).
  • Participants with newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic EGFR-sensitive mutated NSCLC (stage III…
  • Agree to provide fresh or archival tumor tissue.
  • At least one target lesion per the RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →